Trial Radar AI | ||
|---|---|---|
De klinische studie NCT07489482 voor Diabetes mellitus is nog niet rekruterend. Bekijk de kaartweergave van de Klinische Studies Radar en de AI-ontdekkingstools voor alle details. Of stel hier een vraag. | ||
Eén studie komt overeen met de filtercriteria
Kaartweergave
Terug naar zoekresultaten
HENGRUI PHARMAA Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection Fase 1 60 Gerandomiseerd Open-label
Informatie over klinische studies is voornamelijk in het Engels beschikbaar. Trial Radar AI kan echter helpen! Klik op 'Leg studie uit' om de informatie over de studie te bekijken en te bespreken in de taal van uw keuze.
De klinische studie NCT07489482 onderzoekt behandeling bij Diabetes mellitus. Deze Fase 1 interventioneel studie heeft de status nog niet rekruterend. De inclusie van 60 deelnemers begint op 1 maart 2026. De studie wordt geleid door HENGRUI PHARMA en de voltooiing is gepland op 1 december 2026. Laatste update op ClinicalTrials.gov: 24 maart 2026.
Beknopte samenvatting
This study is a randomized, parallel, open-label Phase I clinical trial aimed at comparing the bioavailability and safety of different specifications of SHR-3167 injection, with healthy subjects as the research subjects.
Officiële titel
A Randomized, Parallel, Open-label Clinical Study on the Bioavailability and Safety of Different Specifications of SHR-3167 Injection in Healthy Subjects
Aandoeningen
Diabetes mellitusAndere studie-ID's
- SHR-3167-106
NCT-ID
Startdatum (Werkelijk)
2026-03
Laatste update geplaatst
2026-03-24
Verwachte einddatum
2026-12
Inschrijving (Geschat)
60
Studietype
Interventioneel
FASE
Fase 1
Status
Nog niet rekruterend
Primaire doel
Behandeling
Toewijzing
Gerandomiseerd
Interventiemodel
Parallel
Blindering
Geen (Open-label)
Armen / Interventies
| Deelnemersgroep/Studiearm | Interventie/Behandeling |
|---|---|
ExperimenteelSHR-3167 Injection - Specification A Group | SHR-3167 Injection SHR-3167 injection, different specifications. |
ExperimenteelSHR-3167 Injection - Specification B Group | SHR-3167 Injection SHR-3167 injection, different specifications. |
ExperimenteelSHR-3167 Injection - Specification C Group | SHR-3167 Injection SHR-3167 injection, different specifications. |
Primaire uitkomst
Secundaire uitkomst
| Uitkomstmaat | Beschrijving van de uitkomstmaat | Tijdsbestek |
|---|---|---|
The maximum plasma concentration (Cmax) | Day 1 - Day 71. | |
The area under the blood drug concentration-time curve corresponding from time 0 to the last quantifiable concentration time (AUC0-t) | Day 1 - Day 71. | |
The area under the blood drug concentration-time curve from time 0 to infinity (AUC0-∞) | Day 1 - Day 71. |
| Uitkomstmaat | Beschrijving van de uitkomstmaat | Tijdsbestek |
|---|---|---|
Time to maximum plasma concentration (Tmax) | Day 1 - Day 71. | |
Terminal half-life (t1/2) | Day 1 - Day 71. | |
Apparent volume of distribution (Vz/F) | Day 1 - Day 71. | |
Safety: Incidence and severity of adverse events (AEs) | Day 1 - Day 71. | |
Anti-SHR-3167 antibody (ADA) | Day 1; Day 22; Day 71. | |
Apparent clearance (CL/F) | Day 1 - Day 71. |
Deelname-assistent
Geschiktheidscriteria
Leeftijd van deelnemers
Volwassene
Minimumleeftijd
18 Years
Geslachten die in aanmerking komen voor de studie
Allen
Accepteert gezonde vrijwilligers
Ja
- Male or female: 18 years old to 55 years old (on the day of signing the informed consent form).
- For healthy subjects, the body mass index (BMI) should be between 19.0 kg/m² and 26.0 kg/m², and the weight of men should be ≥ 50 kg and that of women ≥ 45 kg.
- Those who show no abnormalities through physical examination, vital signs, 12-lead electrocardiogram, frontal and lateral chest radiographs and laboratory tests, or have minor abnormalities but are judged by the researcher to have no clinical significance.
- Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must have no plans for conception or sperm/egg donation from the time of signing the informed consent form until 4 months after the last dose, and must voluntarily refrain from unprotected sexual activity within 14 days before the screening period and use effective contraceptive measures (including partners) during the study period; female subjects of childbearing potential must have no unprotected sexual activity in the past 14 days, have a negative pregnancy test during the screening period, and not be in the lactation period.
- During the screening process, the fasting blood glucose should be between 3.9 mmol/L and 6.1 mmol/L, and the glycated hemoglobin (HbA1c) should be no more than 6.0%.
- Understand the research procedures and methods, voluntarily participate and have the ability to comply with the requirements of the trial protocol to complete this trial, and sign the informed consent form in person.
- Those with a history of frequent allergies or allergic diseases, or those who, as judged by the researcher, may be allergic to the study drug or its components or foods, etc.
- Those who have previously suffered from respiratory system, circulatory system, digestive system, urinary system, mental, nervous system, blood system, endocrine system, immune system or malignant tumor diseases, and who, based on the investigator's judgment, are not suitable to participate in this trial.
- Exclude those who had severe infections, severe injuries or surgeries within the previous 12 weeks, or those who plan to undergo surgery during the trial.
- Exclude those who have participated in any clinical trials of other drugs or medical devices within the previous 3 months prior to screening, or those who are still within 5 half-lives of the trial drug at the time of screening (whichever is longer).
- Exclude those who have used any medication (including prescription drugs, over-the-counter drugs, herbal medicines, patent medicines, health supplements, etc.) within the previous 2 weeks up to the time of randomization.
- Positive results were obtained for hepatitis B surface antigen (HBsAg), HIV antibody, Treponema pallidum specific antibody, or hepatitis C virus antibody tests; or the investigator judged that the subject was in the latent or active stage of the aforementioned infections.
- Exclude those who have a history of blood donation within the past 12 weeks, or have suffered from severe blood loss (blood loss ≥ 400 mL), or have received blood transfusion within the past 12 weeks.
- Those who received live (attenuated) vaccines within the previous 1 month or are scheduled to receive such vaccines during the trial process.
- Those who have a history of drug use or substance abuse; or those who tested positive for drugs in the baseline visit.
- Those who have difficulty in venous blood collection or whose physical condition does not allow for blood collection; or those who are expected not to comply well with the protocol or complete the entire trial follow-up.
- Persons with incomplete civil capacity and without a valid guardian.
- The researchers determined that any physical or psychological condition or illness that might increase the risk of the trial, affect the subjects' compliance with the protocol, or prevent the subjects from completing the trial.
HENGRUI PHARMA143 actieve klinische studies om te verkennenCentraal Contactpersoon
Contact: Yanli Dong, +86-0518-82342973, [email protected]
Contact: Weijie Kong, +86-0518-82342973, [email protected]
1 Studielocaties in 1 landen
Hunan
Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China
Gan Zhou, Contact, +86-0731-89753401, [email protected]
Gan Zhou, Hoofdonderzoeker